HealthTronics, IncYesterday after the markets closed, Drug developer Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP) is buying HealthTronics, Inc (NASDAQ: HTRN for $223 million in a move to expand its urology and diagnostic products, the companies said Wednesday.
Endo, based in Chadds Ford, Pa., said it will offer $4.85 per share, marking a 34 percent premium to HealthTronics' closing price of $3.62 on Wednesday. Endo will also assume about $35 million in debt from the Austin, Texas, company. Both companies said their boards of directors approved the deal.
READ THE ENTIRE PRESS RELEASE HERE
Recent Price: $1.24
from the FDA for AEZS-108 in Ovarian Cancer
Before the markets opened this morning, Aeterna Zentaris Inc. (NASDAQ: AEZS), a late-stage drug development company specialized in oncology and endocrinology, announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation for AEZS-108, its doxorubicin targeted conjugate compound, for the treatment of ovarian cancer. AEZS-108 is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.
No comments:
Post a Comment